Calyxt Inc
NASDAQ:CLXT
Intrinsic Value
Calyxt, Inc. is technology company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CLXT.
Calyxt Inc's market capitalization is 155.6m USD.
CLXT stock price is 31.5 USD.
CLXT.
CLXT. Open DCF Valuation
CLXT. Open Relative Valuation
CLXT.
CLXT has positive Gross Profit for the last twelve months.
CLXT's Revenue has dropped by 99% over the past 12 months.
CLXT has negative Operating Income for the last twelve months.
CLXT has negative Net Income for the last twelve months.
CLXT's ROE (Return on Equity) for the past 12 months is negative and is equal to -234%.
CLXT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -120%.
CLXT's short-term assets (55m USD) exceed its short-term liabilties (22m USD).
CLXT's long-term assets (814m USD) exceed its long-term liabilties (330m USD).
CLXT has negative Free Cash Flow for the last twelve months.
CLXT has negative three-year average ROE (Return on Equity): -78%. The company is not efficient at transforming stockholders' equity into net income.
CLXT has negative three-year average ROIC (Return on Invested Capital): -40%. The company is not efficient at using invested capital to generate operating income.
CLXT has negative Net Debt. This means that the company has more cash and short-term investments (51m USD) than debt (2m USD).
CLXT's D/E (Debt to Equity) is very low and is equal to 0.
CLXT's Altman Z-Score is very low and is equal to -15.14.
CLXT doesn't generate enough operating income (-22m USD) to safely cover interest payments on its debt (69k USD).
Fundamental Analysis
Calyxt Inc
Balance Sheet Decomposition
Calyxt Inc
| Current Assets | 4.1m |
| Cash & Short-Term Investments | 3.4m |
| Other Current Assets | 705k |
| Non-Current Assets | 18.3m |
| PP&E | 18.1m |
| Other Non-Current Assets | 158k |
| Current Liabilities | 1.7m |
| Accounts Payable | 340k |
| Accrued Liabilities | 280k |
| Other Current Liabilities | 1m |
| Non-Current Liabilities | 13.5m |
| Other Non-Current Liabilities | 13.5m |
Earnings Waterfall
Calyxt Inc
|
Revenue
|
157k
USD
|
|
Cost of Revenue
|
0
USD
|
|
Gross Profit
|
157k
USD
|
|
Operating Expenses
|
-22.5m
USD
|
|
Operating Income
|
-22.4m
USD
|
|
Other Expenses
|
5.5m
USD
|
|
Net Income
|
-16.9m
USD
|
Free Cash Flow Analysis
Calyxt Inc
CLXT Profitability Score
Profitability Due Diligence
Calyxt Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Calyxt Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
CLXT Solvency Score
Solvency Due Diligence
Calyxt Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Calyxt Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CLXT Price Targets Summary
Calyxt Inc
Ownership
CLXT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CLXT Price
Calyxt Inc
| Average Annual Return | -48.68% |
| Standard Deviation of Annual Returns | 4.67% |
| Max Drawdown | -99% |
| Market Capitalization | 155.6m USD |
| Shares Outstanding | 4 940 693 |
| Percentage of Shares Shorted | 4.71% |
Company Profile
Calyxt Inc
Country
Industry
Market Cap
Dividend Yield
Description
Calyxt, Inc. is technology company. The company is headquartered in Roseville, Minnesota and currently employs 55 full-time employees. The company went IPO on 2017-07-20. The firm is focused on research and development, including gene editing, plant breeding, and trait development. The company specializes in engineering plant metabolisms. The firm operates through the development and commercialization of products derived from plant cells. Its platform provides plant-based synthetic biology solutions to customers across multiple industries. The firm has engineered plant metabolism into products including soybeans with improved fatty-acid profiles and alfalfa able to be better digested by livestock. Its product pipeline includes hemp, winter oats, and high saturated fat soybeans. Hemp serves a range of varieties of materials science needs, including strengthening plastics and reducing petroleum-based content. The firm's customers include seed companies, biotechnology companies, germplasm providers, agricultural processors, and others in the crop’s supply chain and growers.
You don't have any saved screeners yet
